TrialAdvances in therapy2025

A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis.

Kim Papp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.